7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 12026-10-05NCT04886804
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseasesinterstitial lung disease, lung disorder, respiratory system disorderActive, not recruitingPhase 32026-10-02NCT06806592
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progressioninterstitial lung disease, lung disorder, respiratory system disorderRecruitingPhase 32026-10-01NCT07540988
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathiesacquired idiopathic inflammatory myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular diseaseNot yet recruitingPhase 32026-09-30NCT07789015
A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisSkin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosisRecruitingPhase 32026-09-30NCT07497087
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilastidiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorderActive, not recruitingPhase 32026-09-30NCT06238622
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsSolid TumoursRecruitingPhase 22026-09-29NCT06581432